Understanding the Market | DUALITYBIO-B opened over 4% higher after being included in the Hang Seng Composite Index constituents, and its new breast cancer drug has reached the primary endpoint in Phase III clinical trials
I'm PortAI, I can summarize articles.
DUALITYBIO-B's stock price opened over 4% higher, rising 4.63% to HKD 380 as of the time of writing, with a transaction volume of HKD 7.506 million. Starting from September 8, 2025, the company's shares will be included in the Hang Seng Composite Index constituents, expanding the investor base. The company also announced that its new breast cancer drug DB-1303/BNT323 has reached its primary endpoint in the Phase III clinical trial and plans to communicate with the drug regulatory authority regarding the application for market approval
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments